Immunome Investor Relations Material

Immunome, Inc. is a biotechnology company focused on developing targeted cancer therapies. The company leverages a proprietary discovery platform to identify novel antigens and develop corresponding therapies, particularly in the field of oncology. Immunome's product pipeline includes several candidates, such as AL102, a gamma secretase inhibitor currently in Phase 3 trials for the treatment of desmoid tumors, and other preclinical assets aimed at targeting specific cancer markers through various therapeutic approaches, including antibody-drug conjugates (ADCs) and radioligand therapies. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.